The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of capecitabine (Cape), oxaliplatin (Ox), panitumumab (Pmab), and external beam radiation therapy (RT) for patients with esophagogastric carcinoma (EC).
Brian G. Czito
Research Funding - Amgen
Christopher Willett
No relevant relationships to disclose
Manisha Palta
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Shannon McCall
No relevant relationships to disclose
Nathan Gee
No relevant relationships to disclose
Herbert Hurwitz
Consultant or Advisory Role - Amgen
Research Funding - Amgen
R Edward Coleman
No relevant relationships to disclose
Yousuf Zafar
No relevant relationships to disclose
Paula Kennedy-Newton
No relevant relationships to disclose
Hope Uronis
Research Funding - Amgen